These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29602796)

  • 1. Survival rate and predictors of mortality in patients hospitalised with heart failure: a cohort study on the data of Persian registry of cardiovascular disease (PROVE).
    Givi M; Shafie D; Nouri F; Garakyaraghi M; Yadegarfar G; Sarrafzadegan N
    Postgrad Med J; 2018 Jun; 94(1112):318-324. PubMed ID: 29602796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival.
    Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Nielsen JC
    Eur Heart J Cardiovasc Pharmacother; 2015 Jul; 1(3):182-8. PubMed ID: 27533993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial.
    Fiuzat M; Wojdyla D; Pina I; Adams K; Whellan D; O'Connor CM
    JACC Heart Fail; 2016 Feb; 4(2):109-115. PubMed ID: 26519996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-Blockers and ACE Inhibitors Are Associated with Improved Survival Secondary to Ventricular Tachyarrhythmia.
    Schupp T; Behnes M; Weiß C; Nienaber C; Lang S; Reiser L; Bollow A; Taton G; Reichelt T; Ellguth D; Engelke N; Ansari U; El-Battrawy I; Bertsch T; Akin M; Mashayekhi K; Borggrefe M; Akin I
    Cardiovasc Drugs Ther; 2018 Aug; 32(4):353-363. PubMed ID: 30074111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of clinical characteristics and management on the prognosis of unselected heart failure patients.
    Eschalier R; Chenaf C; Mulliez A; Yalioua A; Clerfond G; Authier N; Vorilhon C; Citron B; Pereira B; Jean F; Souteyrand G; Motreff P; Eschalier A; Lusson JR
    Cardiovasc Drugs Ther; 2015 Feb; 29(1):89-98. PubMed ID: 25700624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospitalisation length and prognosis in heart failure patients.
    Zaprutko J; Michalak M; Nowicka A; Dankowski R; Drożdż J; Ponikowski P; Opolski G; Nessler J; Nowalany-Kozielska E; Szyszka A
    Kardiol Pol; 2017; 75(4):323-331. PubMed ID: 27995602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry.
    De Blois J; Fagerland MW; Grundtvig M; Semb AG; Gullestad L; Westheim A; Hole T; Atar D; Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2015 Jan; 1(1):31-6. PubMed ID: 27533962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heart failure medications prescribed at discharge for patients with left ventricular assist devices.
    Shreibati JB; Sheng S; Fonarow GC; DeVore AD; Yancy CW; Bhatt DL; Schulte P; Peterson ED; Hernandez A; Heidenreich PA
    Am Heart J; 2016 Sep; 179():99-106. PubMed ID: 27595684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of benefit and early hazard of bucindolol for Class IV heart failure.
    Anderson JL; Krause-Steinrauf H; Goldman S; Clemson BS; Domanski MJ; Hager WD; Murray DR; Mann DL; Massie BM; McNamara DM; Oren R; Rogers WJ;
    J Card Fail; 2003 Aug; 9(4):266-77. PubMed ID: 13680547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adaptation of guidelines for the treatment of chronic heart failure in a specialized heart failure clinic].
    Pölzl G; Gouya G; Hügel H; Frick M; Ulmer H; Pachinger O
    Wien Klin Wochenschr; 2002 Oct; 114(19-20):833-9. PubMed ID: 12503474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score-matched cohort study.
    Edner M; Benson L; Dahlström U; Lund LH
    Eur Heart J; 2015 Sep; 36(34):2318-26. PubMed ID: 26069212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003.
    Lamb DA; Eurich DT; McAlister FA; Tsuyuki RT; Semchuk WM; Wilson TW; Blackburn DF
    Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):228-35. PubMed ID: 20031842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
    O'Connor CM; Abraham WT; Albert NM; Clare R; Gattis Stough W; Gheorghiade M; Greenberg BH; Yancy CW; Young JB; Fonarow GC
    Am Heart J; 2008 Oct; 156(4):662-73. PubMed ID: 18926148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-variable risk model in men and women with heart failure.
    Chyu J; Fonarow GC; Tseng CH; Horwich TB
    Circ Heart Fail; 2014 Jan; 7(1):88-95. PubMed ID: 24281135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of the optimal neurohormonal blockade on long-term survival in patients with chronic heart failure].
    Roik M; Starczewska MH; Stawicki S; Huczek Z; Kochanowski J; Oreziak A; Furmańczyk A; Opolski G
    Pol Arch Med Wewn; 2006 Apr; 115(4):321-8. PubMed ID: 17078490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between beta-blocker and angiotensin-converting enzyme inhibitor dose and clinical outcome following acute myocardial infarction.
    Grall S; Biere L; Le Nezet M; Bouvier JM; Lucas-Chauvelon P; Richard C; Abi-Khalil W; Delepine S; Prunier F; Furber A
    Circ J; 2015; 79(3):632-40. PubMed ID: 25746548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009.
    Staszewsky L; Cortesi L; Tettamanti M; Dal Bo GA; Fortino I; Bortolotti A; Merlino L; Latini R; Roncaglioni MC; Baviera M
    Eur J Heart Fail; 2016 Jul; 18(7):840-8. PubMed ID: 27098360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.